MedTrace Logo

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

NCT02385669 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2020-05-05

Study results available
· View outcomes & findings →

Summary

This study evaluates whether it is safe to administer a peptide vaccine with ipilimumab. This study will also evaluate the effects of the combination of the peptide vaccine and ipilimumab on the immune system. The investigators will monitor these effects by performing tests in the laboratory on participants' blood, a lymph node, and tumor samples.

Conditions

Interventions

DRUG

Ipilimumab

Checkpoint blockade inhibitor

BIOLOGICAL

6MHP

6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides

Sponsors & Collaborators

  • Craig L Slingluff, Jr

    lead OTHER

Principal Investigators

  • Elizabeth Gaughan, MD · University of Virginia

  • Craig L. Slingluff, Jr., MD · University of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-09-18
Completion
2019-09-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02385669 on ClinicalTrials.gov